Israeli Jews

Benitec Biopharma Appoints Edward Smith to the Board of Directors

Retrieved on:

Wednesday, April 15, 2020

HAYWARD, Calif., April 14, 2020 /PRNewswire/ --Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors.

Key Points:

HAYWARD, Calif., April 14, 2020 /PRNewswire/ --Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors.
Edward brings more than 20 years of experience in executive finance and operations leadership in the biotechnology industry to Benitec's Board of Directors.
Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma, Inc. commented on Mr. Smith's appointment, "Edward's extensive background in finance and operations in the biotherapeutics space will make him an exceptional contributor to the Board.
Benitec Biopharma, Inc. ("Benitec" or the "Company") is a development-stage biotechnology company focused on the advancement of novel genetic medicines, with headquarters in Hayward, California.

BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors

Retrieved on:

Tuesday, March 31, 2020

Israeli Jews, American International Group, Jacob A. Frenkel, Peterson Institute for International Economics, Organizations, Frenkel, Group of Thirty, Brainstorm

Prof. Frenkel is joining our Board as Chairman at a crucial time where his leadership will add tremendous value, stated Chaim Lebovits, President and CEO of BrainStorm.

Key Points:

Prof. Frenkel is joining our Board as Chairman at a crucial time where his leadership will add tremendous value, stated Chaim Lebovits, President and CEO of BrainStorm.
Prof. Frenkel said, I am honored to join BrainStorm as Chairman of the Board of Directors.
Jacob Frenkel, Ph.D., currently serves as Chairman of the Board of Trustees of the Group of Thirty (G-30), a private, nonprofit, consultative group on international economic and monetary affairs.
He serves as Chairman of the Board of Governors of Tel Aviv University, where he is also Chairman of the Frenkel-Zuckerman Institute for Global Economics.

Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations

Retrieved on:

Thursday, March 12, 2020

Israeli Jews

He will act as both a senior advisor to the newly formed committee and will also join the company's existing Scientific Advisory Board.

Key Points:

He will act as both a senior advisor to the newly formed committee and will also join the company's existing Scientific Advisory Board.
The Technology Evaluation, Acquisition and Scientific Integrity Board Committee is expected to be composed of the following MindMed board members: Executive Chairman & Co-CEO Stephen Hurst, Board Director & Senior Advisor Miri Halperin Wernli, and Director & Co-CEO JR Rahn.
The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines.
MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:BGHM.

CannaTech Tel Aviv & PsyTech Summit Postponed

Retrieved on:

Tuesday, March 3, 2020

Tel Aviv, Israeli Jews, Association football

TEL AVIV, Israel, March 3, 2020 /PRNewswire/ -- In light of developing circumstances with theCOVID-19 coronavirusand based on recommendations from the Israeli Ministry of Health, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC),CannaTech Tel Aviv and PsyTechSummit are postponed.

Key Points:

TEL AVIV, Israel, March 3, 2020 /PRNewswire/ -- In light of developing circumstances with theCOVID-19 coronavirusand based on recommendations from the Israeli Ministry of Health, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC),CannaTech Tel Aviv and PsyTechSummit are postponed.
PsyTech Summit will take place June 14-15 and CannaTech, June 15-16, 2020.
Saul Kaye, CEO of iCAN: Israel-Cannabiscommented:"Our number one concern is the health and safety of our attendees and speakers, our partners, our colleagues and our vendors.While we are disappointed to postpone both CannaTech Tel Aviv & PsyTech Summit, we are very confident it will be worth the wait.
PsyTech Summit is the global industry event for innovation in psychedelic medicine.

Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

Retrieved on:

Monday, March 2, 2020

Israeli Jews, Jeremy Levin

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Alexander Kolevzon, M.D., a leader in child and adolescent psychiatry, to its Scientific Advisory Board (SAB).

Key Points:

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Alexander Kolevzon, M.D., a leader in child and adolescent psychiatry, to its Scientific Advisory Board (SAB).
We welcome Dr. Kolevzon to our scientific advisory board.
He is a world-renowned expert in neurodevelopmental disorders, and his experience and knowledge complement the capabilities already embodied by our other scientific advisors.
Ovid Therapeutics Inc.is aNew York-based biopharmaceutical company using its BoldMedicineapproach to develop medicines that transform the lives of patients with rare neurological disorders.

Delek US and Delek Logistics Announce Chief Financial Officer Transition

Retrieved on:

Tuesday, February 25, 2020

Companies, Delek US, Delek, DK, Economy of Israel, Israeli Jews, Yossi Abu

BRENTWOOD, Tenn., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Delek US Holdings, Inc. (NYSE: DK) (Delek US) and Delek Logistics Partners, LP (NYSE: DKL) (Delek Logistics) today announced that Mr. Assi Ginzburg, Executive Vice President and Chief Financial Officer, has informed them that he will not renew his employment contract to pursue other opportunities.

Key Points:

BRENTWOOD, Tenn., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Delek US Holdings, Inc. (NYSE: DK) (Delek US) and Delek Logistics Partners, LP (NYSE: DKL) (Delek Logistics) today announced that Mr. Assi Ginzburg, Executive Vice President and Chief Financial Officer, has informed them that he will not renew his employment contract to pursue other opportunities.
Delek US and Delek Logistics Partners are in the process of identifying Mr. Ginzburgs replacement.
Regarding the CFO transition, Uzi Yemin, Chairman, President and Chief Executive Officer of Delek US and Chairman and Chief Executive Officer of Delek Logistics GP, the general partner of Delek Logistics, stated, Delek would not be what it is today without Assis invaluable contributions since joining the company in 2004.
Delek US and its affiliates also own approximately 63 percent (including the 2 percent general partner interest) of Delek Logistics.

Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

Retrieved on:

Tuesday, February 25, 2020

Israeli Jews, Jeremy Levin, Business

NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at3:30 p.m. EST.

Key Points:

NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at3:30 p.m. EST.
The conference will be held at the Boston Marriot Copley Place in Boston, MA.
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders.
Ovid is also developing OV935/TAK935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

ILAN Mexico Founder Meets with Israeli Prime Minister to Continue Building Bilateral Ties and Support

Retrieved on:

Thursday, February 20, 2020

Western Asia, Geography of Asia, Middle East, Israeli Jews, Benjamin Netanyahu, Shimon Peres, Israel, Netanyahu, Ilan

JERUSALEM, Feb. 20, 2020 /PRNewswire/ -- Isaac Assa, Founder and President of the Israel Latin American Network (ILAN), met with the Prime Minister of Israel, Benjamin Netanyahu, yesterday, February 19, 2020.

Key Points:

JERUSALEM, Feb. 20, 2020 /PRNewswire/ -- Isaac Assa, Founder and President of the Israel Latin American Network (ILAN), met with the Prime Minister of Israel, Benjamin Netanyahu, yesterday, February 19, 2020.
The meeting focused on the continued strengthening of existing ties, support and actions between Israel, Mexico and Latin America.
The first edition of the ILAN Awards, inspired by Shimon Peres, which was held on January 16, 2020 in Mexico City.
SOCIAL TRANSFORMATION: Rutopa, a community of travelers who live unique experiences offered by local hosts in indigenous communities throughout Mexico.

BiomX Announces Dual Listing on the Tel-Aviv Stock Exchange

Retrieved on:

Monday, February 3, 2020

Biotechnology, Health, Science, Research, Oncology, Tel Aviv Stock Exchange, Tase, Stock exchanges, Tel Aviv, Western Asia, Middle East, Israeli Jews, Kenon Holdings

(NYSE:PHGE), a clinical-stage biotechnology company developing both natural and engineered phage therapies, today announced that the Tel Aviv Stock Exchange (TASE) has approved the listing of its common shares, with trading effective February 6th, 2020.

Key Points:

(NYSE:PHGE), a clinical-stage biotechnology company developing both natural and engineered phage therapies, today announced that the Tel Aviv Stock Exchange (TASE) has approved the listing of its common shares, with trading effective February 6th, 2020.
We are excited to begin trading on the Tel Aviv Stock Exchange in Israel, the country in which we were founded and are headquartered, said BiomX CEO Jonathan Solomon.
We are proud to provide another route for Israeli investors to participate in our growth as a leading developer of targeted phage products.
Ittai Ben Zeev, CEO of TASE, congratulated BiomX for joining the Tel Aviv Stock Exchange as a dual listed company.

Finastra Strengthens Its Position in Israel With New Office Opening

Retrieved on:

Monday, January 27, 2020

Finastra, Israeli Jews, Finance, Money, Economy

TEL AVIV, Israel, Jan. 27, 2020 /PRNewswire/ -- Finastra is investing further in Israel with a new office in Kfar Saba, just outside Tel Aviv.

Key Points:

TEL AVIV, Israel, Jan. 27, 2020 /PRNewswire/ -- Finastra is investing further in Israel with a new office in Kfar Saba, just outside Tel Aviv.
The office, which is home to over 330 employees, offers more space for the Finastra team to grow as the company strengthens its position in the country, and provides an ultra-modern workspace to inspire creativity and facilitate collaboration.
Eli Rosner, Chief Product and Technology Officer at Finastra, said, "Finastra has been operating in Israel for many years, and during the last few, we've seen a surge in the number of fintech developments.
Sagive Greenspan, SVP, General Manager, Payments and General Manager of Finastra Israel said, "Israel has been Finastra's main hub for payments for many years.